PubMed Health⌕ Search

PubMed · 10407246

Bootstrap methods for adaptive designs.

Abstract

Adaptive designs generate dependent sequences of random variables that are not exchangeable. Therefore, it is not obvious how to employ a resampling scheme for confidence interval estimation. We propose a simple procedure where observed response rates from an adaptive experiment are input to a simulation program. The program then generates sequences from the adaptive sampling scheme. We compare, via simulation, three bootstrap confidence intervals with the asymptotic confidence interval for two adaptive designs useful for clinical trials. A simple ranking of simulated response rates yields a confidence interval approximation with coverage close to 1-alpha in most cases. The method allows us to incorporate such complexities as staggered entry and delayed response. We give an example of its utility on a clinical trial of fluoxetine in depression.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

W F Rosenberger, F Hu. 1999-07-30. Bootstrap methods for adaptive designs.. https://doi.org/10.1002/(sici)1097-0258(19990730)18%3A14%3C1757%3A%3Aaid-sim212%3E3.0.co%3B2-r

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Rapid determination of citalopram in human plasma by high-performance liquid chromatography.

A rapid high-performance liquid chromatographic method for the quantitation of citalopram in human plasma is presented. The sample preparation involved liquid-liquid extraction of citalopram with hexane-isoamyl alcohol (98:2 v/v) and back-extraction of the drug to 0.02 M hydrochloric acid. Liquid chromatography was performed on a cyano column (45 x 4.6 mm, 5 microm particles), the mobile phase consisted of an acetonitrile-phosphate buffer, pH 6.0 (50:50, v/v). The run time was 2.6 min. The fluorimetric detector was set at an excitation wavelength of 236 nm and an emission wavelength of 306 nm. Verapamil was used as the internal standard. The limit of quantitation was 0.96 ng/ml using 1 ml of plasma. Within- and between-day precision expressed by relative standard deviation was less than 7% and inaccuracy did not exceed 6%. The assay was applied to the analysis of samples from a pharmacokinetic study.

Antidepressive Agents, Second-Generation↗

[Sibutramine--antidepressive agent tested against obesity].

Eight European centers recruited 605 obese patients (BMI 30-45 kg/m2) for a six month period of weight loss with sibutramine (10 mg/d) combined with an individualized 600 kcal/d deficit. 467 (77%) patients with > 5% weight loss were then randomized to sibutramine (10 mg/day) and placebo groups over a further 18 months. Initially weight loss progressed to a total of -11.3 +/- 5.5 kg. After randomization the placebo group regained weight to -4.7 +/- 7.2 kg from baseline at 2 years; the sibutramine group only showed slight weight regain to -10.2 kg +/- 9.3 kg (mean group difference 5.5 kg, 95% C.I. 2.9, 8.1, p < 0.001). VLDL fell and HDL increased more than expected by weight loss. Twenty (3%) patients were withdrawn because of increases in blood pressure. This individualized management program achieves metabolically significant and sustained weight loss in 77% of obese patients.

Antidepressive Agents, Second-Generation↗